基本信息
浏览量:3
职业迁徙
个人简介
Research Summary
The major goal of the laboratory is to dissect and pharmacologically target intracellular proteins to induce cancer cell death and manipulate the immune response. We are currently applying new research tools and prototype therapeutics that we, and others, have developed to target the BCL-2 family of proteins and other cell signaling proteins in immune cells. A large part of our lab focuses on using portions of the actual proteins, or peptides, as drugs and biological tools to uncover specific molecular pathways in diseased and normal cells. Peptide-based therapeutics have enormous potential for immune modulation and direct cancer treatment but have traditionally lacked efficient stabilization and delivery within patients, and thereby, have had limited clinical applications. To are working to overcome these barriers within the lab and through collaboration with nanotechnologists and chemical engineers. Overall, we are committed to translation of our findings to pediatric and adult patients with cancer and immune system disease. While performing research at the University of Chicago, we are in close proximity to scientists, clinicians, and patients and are deeply committed to working collaboratively with these groups to make significant inroads in treating those suffering from refractory disease.
The major goal of the laboratory is to dissect and pharmacologically target intracellular proteins to induce cancer cell death and manipulate the immune response. We are currently applying new research tools and prototype therapeutics that we, and others, have developed to target the BCL-2 family of proteins and other cell signaling proteins in immune cells. A large part of our lab focuses on using portions of the actual proteins, or peptides, as drugs and biological tools to uncover specific molecular pathways in diseased and normal cells. Peptide-based therapeutics have enormous potential for immune modulation and direct cancer treatment but have traditionally lacked efficient stabilization and delivery within patients, and thereby, have had limited clinical applications. To are working to overcome these barriers within the lab and through collaboration with nanotechnologists and chemical engineers. Overall, we are committed to translation of our findings to pediatric and adult patients with cancer and immune system disease. While performing research at the University of Chicago, we are in close proximity to scientists, clinicians, and patients and are deeply committed to working collaboratively with these groups to make significant inroads in treating those suffering from refractory disease.
研究兴趣
论文共 87 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Transplantation and Cellular Therapyno. 2 (2023): S124-S125
引用0浏览0引用
0
0
Blood Advancesno. 10 (2023): 2153-2154
引用0浏览0WOS引用
0
0
Caner Saygin, Giorgia Giordano, Kathryn Shimamoto,Bart Eisfelder,Anika Thomas-Toth,Girish Venkataraman,Vijayalakshmi Ananthanarayanan,Tiffaney L Vincent,Adam DuVall,Anand A Patel,Yi Chen,Fenlai Tan,
Clinical cancer research : an official journal of the American Association for Cancer Researchno. 16 (2023): 3151-3161
引用0浏览0WOS引用
0
0
Mirielle Nauman,Daniele Vanni, Nicole Arellano, Thao Trang Nguyen,James LaBelle,Caner Saygin,Silvia Catricala,Ilaria Carola Casetti,Oscar Borsani,Elisa Rumi,Daniela Pietra,Shannon Elf
BLOOD (2023): 3148
Caner Saygin, Giorgia Giordano, Kathryn Shimamoto, Bart Eisfelder, Anika Thomas-Toth,Girish Venkataraman,Vijayalakshmi Ananthanarayanan,Tiffaney L. Vincent,Adam DuVall,Anand A. Patel, Yi Chen,Fenlai Tan,
crossref(2023)
Akshay Sharma,Jaap-Jan Boelens,Maria Cancio,Jane S Hankins, Prafulla Bhad, Marjohn Azizy,Andrew Lewandowski,Xiaojun Zhao,Shripad Chitnis,Radhika Peddinti,Yan Zheng,Neena Kapoor,
Transplantation and Cellular Therapyno. 2 (2023): S142-S143
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn